Drug Profile
Research programme: rheumatoid arthritis therapies - Cytoguide
Latest Information Update: 10 Oct 2012
Price :
$50
*
At a glance
- Originator Cytoguide
- Class Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 09 Oct 2012 No development reported for Rheumatoid arthritis in Denmark (unspecified route)